Loading stock data…
MeiraGTx Holdings plc (MGTX)
$11.77-0.33 (-2.73%)
Market ClosedLast close Jul 24
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MeiraGTx Holdings plc in the Healthcare sector is trading at $11.77 with a market capitalization of $870M. Wall Street consensus targets $28.38 (8 analysts), implying a +141.1% move over the next 12 months. The stock is currently 23% below its 52-week high of $15.35, remaining 30.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +141.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $293,000↓ | $75.36M↑ | $410,000↓ | $3.69M↑ | $1.93M |
| Gross Profit | $95,000↓ | $74.89M↑ | $97,000↓ | $1.01M↑ | $548,000 |
| Operating Income | -$40.82M↓ | $26.47M↑ | -$46.05M↓ | -$44.79M↓ | -$41.60M |
| Net Income | -$46.31M↓ | $15.09M↑ | -$50.51M↓ | -$38.80M↑ | -$39.98M |
Peer Comparison
JNJUNHPFE
Fundamentals
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degene...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$869.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
207.35%
Volume
Today's trading volume
473,678
Recent News
Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?
The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What This MeiraGTx Insider Sale Might Mean With Two Drug Filings Near
Stuart Naylor's 4% portfolio reduction follows an 89% one-year stock surge, executed under a pre-scheduled Rule 10b5-1 trading plan adopted in December 2025.
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Top Midday Gainers
Vertex Pharmaceuticals (VRTX) and Crinetics Pharmaceuticals (CRNX) said late Monday they have reache
Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint
MeiraGTx Holdings PLC (NASDAQ:MGTX) is one of the best gene therapy stocks to buy in 2026. The stock has gained around 25% year-to-date and soared more than 95% over the past year. Looking ahead, analysts believe the stock could explode more than 100% in the next 12 months as MeiraGTx advances its various therapy programs. […]